作者:Jeremy P. Mallari、Anang A. Shelat、Aaron Kosinski、Conor R. Caffrey、Michele Connelly、Fangyi Zhu、James H. McKerrow、R. Kiplin Guy
DOI:10.1021/jm900908p
日期:2009.10.22
target. Herein we report the structure-guided development of TbcatB inhibitors with specificity relative to rhodesain and human cathepsins B and L. Inhibitors were tested for enzymatic activity, trypanocidal activity, and general cytotoxicity. These data chemically validate TbcatB as a drug target and demonstrate that it is possible to potently and selectively inhibit TbcatB relative to trypanosomal
锥虫组织蛋白酶 TbcatB 是寄生虫生存所必需的,是一个有吸引力的治疗目标。在此,我们报告了 TbcatB 抑制剂的结构引导开发,其具有相对于罗得沙因和人类组织蛋白酶 B 和 L 的特异性。测试了抑制剂的酶活性、杀锥虫活性和一般细胞毒性。这些数据在化学上验证了 TbcatB 作为药物靶点,并证明相对于锥虫和人类同源物,有可能有效和选择性地抑制 TbcatB。